Laura DeForge

8.4k total citations · 1 hit paper
54 papers, 5.8k citations indexed

About

Laura DeForge is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Laura DeForge has authored 54 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Immunology, 23 papers in Molecular Biology and 22 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Laura DeForge's work include Monoclonal and Polyclonal Antibodies Research (19 papers), Immune Response and Inflammation (11 papers) and Cell Adhesion Molecules Research (7 papers). Laura DeForge is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (19 papers), Immune Response and Inflammation (11 papers) and Cell Adhesion Molecules Research (7 papers). Laura DeForge collaborates with scholars based in United States, France and Switzerland. Laura DeForge's co-authors include Daniel G. Remick, Jeanine L. Bussiere, J. Kenney, Avi Ashkenazi, David A. Lawrence, Scot A. Marsters, Hartmut Koeppen, Iphigenia L. Koumenis, Zahra Shahrokh and Andrea Hebert and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Laura DeForge

53 papers receiving 5.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 1.9k citations Avi Ashkenazi, Sharon Fong et al. Journal of Clinical Investigation profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Laura DeForge	3.2k	2.5k	1.1k	877	789	54	5.8k
Richard C. Duke	3.5k 1.1×	2.5k 1.0×	942 0.8×	631 0.7×	603 0.8×	51	6.5k
Brian M. J. Foxwell	1.7k 0.5×	3.2k 1.3×	1.0k 0.9×	710 0.8×	1.3k 1.6×	69	5.8k
Susheela Tridandapani	3.1k 1.0×	3.0k 1.2×	1.1k 0.9×	413 0.5×	742 0.9×	115	6.4k
William J. Kohr	3.3k 1.0×	2.5k 1.0×	1.0k 0.9×	538 0.6×	1.4k 1.8×	39	7.6k
Drake LaFace	3.1k 1.0×	3.7k 1.5×	1.1k 1.0×	545 0.6×	453 0.6×	48	6.9k
Francesco Novelli	2.3k 0.7×	3.5k 1.4×	2.5k 2.2×	751 0.9×	1.2k 1.5×	157	7.1k
Nancy C. Fiore	1.4k 0.4×	2.3k 0.9×	929 0.8×	465 0.5×	588 0.7×	23	4.6k
Ralph C. Budd	3.0k 1.0×	4.1k 1.6×	975 0.9×	694 0.8×	734 0.9×	116	6.9k
Irene S. Figari	1.5k 0.5×	2.6k 1.0×	1.1k 1.0×	619 0.7×	488 0.6×	11	4.8k
Glenn E. Nedwin	2.3k 0.7×	3.0k 1.2×	1.3k 1.1×	461 0.5×	504 0.6×	21	6.1k

Countries citing papers authored by Laura DeForge

Since Specialization

Citations

This map shows the geographic impact of Laura DeForge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura DeForge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura DeForge more than expected).

Fields of papers citing papers by Laura DeForge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura DeForge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura DeForge. The network helps show where Laura DeForge may publish in the future.

Co-authorship network of co-authors of Laura DeForge

This figure shows the co-authorship network connecting the top 25 collaborators of Laura DeForge. A scholar is included among the top collaborators of Laura DeForge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura DeForge. Laura DeForge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loyet, Kelly M., Xiangdan Wang, Jihong Yang, et al.. (2014). Complement Inhibition in Cynomolgus Monkeys by Anti–Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration. Journal of Pharmacology and Experimental Therapeutics. 351(3). 527–537. 40 indexed citations

Kozak, Katherine R., Jianyong Wang, Josefa Chuh, et al.. (2013). Micro-volume wall-less immunoassays using patterned planar plates. Lab on a Chip. 13(7). 1342–1342. 16 indexed citations

Deng, Rong, Y. Gloria Meng, Kwame Hoyte, et al.. (2012). Subcutaneous bioavailability of therapeutic antibodies as a function  of FcRn binding affinity in mice. mAbs. 4(1). 101–109. 66 indexed citations

Campagne, Menno van Lookeren, Kenneth J. Katschke, Ping Wu, et al.. (2010). Targeting the Alternative Pathway of Complement in AMD With a Factor D Selective Antibody. Investigative Ophthalmology & Visual Science. 51(13). 4511–4511. 2 indexed citations

Loyet, Kelly M., Manda Wong, Alyssa Morimoto, et al.. (2010). Anti-Factor D Fab Specifically Inhibits the Alternative Complement Pathway: In vitro Characterization and in vivo Effects Following Administration to Cynomolgus Monkeys. Investigative Ophthalmology & Visual Science. 51(13). 2980–2980. 1 indexed citations

DeForge, Laura, Kelly M. Loyet, Donnie Delarosa, et al.. (2010). Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. Journal of Immunological Methods. 362(1-2). 70–81. 26 indexed citations

Li, Bing, Hongkang Xi, Lauri Diehl, et al.. (2009). Improving Therapeutic Efficacy of a Complement Receptor by Structure-based Affinity Maturation. Journal of Biological Chemistry. 284(51). 35605–35611. 9 indexed citations

Katschke, Kenneth J., Scott Stawicki, Jianping Yin, et al.. (2009). Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of Complement. Journal of Biological Chemistry. 284(16). 10473–10479. 48 indexed citations

DeForge, Laura, Danny Shih, Derek Kennedy, et al.. (2007). Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL. Journal of Immunological Methods. 320(1-2). 58–69. 8 indexed citations

10.

Lee, Chingwei V., S.G. Hymowitz, Heidi J.A. Wallweber, et al.. (2006). Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood. 108(9). 3103–3111. 48 indexed citations

11.

DeForge, Laura, Andrea G. Cochran, Sherry Yeh, et al.. (2004). Substrate Capacity Considerations in Developing Kinase Assays. Assay and Drug Development Technologies. 2(2). 131–140. 6 indexed citations

12.

Kelley, Robert F., Klára Tótpál, Mary Mathieu, et al.. (2004). Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling. Journal of Biological Chemistry. 280(3). 2205–2212. 234 indexed citations

13.

Meng, Gloria, W L Wong, David A. Lawrence, et al.. (2003). Design, Construction, and In Vitro Analyses of Multivalent Antibodies. The Journal of Immunology. 170(9). 4854–4861. 41 indexed citations

14.

Ashkenazi, Avi, Sharon Fong, Susan W.S. Leung, et al.. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation. 104(2). 155–162. 1892 indexed citations breakdown →

15.

Leong, Steven R., C A Hébert, Henry B. Lowman, et al.. (1997). IL-8 single-chain homodimers and heterodimers: Interactions with the chemokine receptors CXCR1, CXCR2, and DARC. Protein Science. 6(3). 609–617. 43 indexed citations

16.

Lowman, Henry B., et al.. (1996). Exchanging Interleukin-8 and Melanoma Growth-stimulating Activity Receptor Binding Specificities. Journal of Biological Chemistry. 271(24). 14344–14352. 70 indexed citations

17.

Fischer, E, Michael A. Marano, Kimberly J. Van Zee, et al.. (1992). Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.. Journal of Clinical Investigation. 89(5). 1551–1557. 250 indexed citations

18.

Remick, Daniel G., et al.. (1992). Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer Reaction of relapsing fever.. The Journal of Experimental Medicine. 175(5). 1207–1212. 87 indexed citations

19.

Remick, Daniel G., Laura DeForge, James F. Sullivan, & Henry J. Showell. (1992). Profile of Cytokines in Synovial Fluid Specimens from Patients with Arthritis. Interleukin 8 (IL-8) and IL-6 Correlate with Inflammatory Arthritides. Immunological Investigations. 21(4). 321–327. 39 indexed citations

20.

Rodríguez, Jorge L., Cathie G. Miller, Laura DeForge, et al.. (1992). LOCAL PRODUCTION OF INTERLEUKIN-8 IS ASSOCIATED WITH NOSOCOMIAL PNEUMONIA. The Journal of Trauma: Injury, Infection, and Critical Care. 33(1). 74–82. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact